Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies

Gianluca Mauri, Elio Gregory Pizzutilo, Alessio Amatu, Katia Bencardino, Laura Palmeri, Erica Francesca Bonazzina, Federica Tosi, Giulia Carlo Stella, Giovanni Burrafato, Francesco Scaglione, Silvia Marsoni, Giulia Siravegna, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi

Research output: Contribution to journalReview article

Abstract

BACKGROUND: Despite advances in precision oncology and immunotherapy of tumors, little progress has been made in metastatic colorectal cancer (mCRC) in recent years. Therefore, making the most of available therapies is a necessity. Several studies, based on the pulsatile behavior of RAS clones under EGFR blockade, investigated whether readministration of EGFR-targeted agents is effective beyond second line.

METHODS: A systematic review of studies of retreatment with anti-EGFR monoclonal antibodies has been performed from January 2005 to December 2018 according to PRISMA criteria from PubMed, ESMO and ASCO meetings libraries and Clinicaltrial.gov. Efficacy has been evaluated as objective response rate and survival in available publications. In addition, type and incidence of side effects occurring during on anti-EGFR retreatment have been considered.

RESULTS: 26 publications have been retrieved, of which 20 full-text articles and 6 abstracts and categorized as for the retreatment strategy into five groups: rechallenge (n = 10), reintroduction (n = 4), sequence (n = 5), dose escalation (n = 1) and mixed (n = 6). Data of efficacy displayed high heterogeneity across different strategies (objective response rate, ORR = 0.0-53.8%; disease control rate, DCR = 24.0-89.7%), with best results in the setting of rechallenge (ORR = 2.9-53.8%; DCR = 40.0-89.7%).

CONCLUSIONS: Rechallenge with anti-EGFR provides clinical benefit in molecularly selected mCRC patients beyond second line. Further ctDNA-guided studies comparing this option of treatment with current approved advanced line treatments are warranted.

Original languageEnglish
Pages (from-to)41-53
Number of pages13
JournalCancer Treatment Reviews
Volume73
DOIs
Publication statusE-pub ahead of print - Dec 27 2018

Fingerprint

Retreatment
Colorectal Neoplasms
Monoclonal Antibodies
Publications
PubMed
Immunotherapy
Libraries
Therapeutics
Survival Rate
Clone Cells
Incidence
Neoplasms

Cite this

Mauri, G., Pizzutilo, E. G., Amatu, A., Bencardino, K., Palmeri, L., Bonazzina, E. F., ... Sartore-Bianchi, A. (2018). Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treatment Reviews, 73, 41-53. https://doi.org/10.1016/j.ctrv.2018.12.006

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer : Systematic review of different strategies. / Mauri, Gianluca; Pizzutilo, Elio Gregory; Amatu, Alessio; Bencardino, Katia; Palmeri, Laura; Bonazzina, Erica Francesca; Tosi, Federica; Carlo Stella, Giulia; Burrafato, Giovanni; Scaglione, Francesco; Marsoni, Silvia; Siravegna, Giulia; Bardelli, Alberto; Siena, Salvatore; Sartore-Bianchi, Andrea.

In: Cancer Treatment Reviews, Vol. 73, 27.12.2018, p. 41-53.

Research output: Contribution to journalReview article

Mauri, G, Pizzutilo, EG, Amatu, A, Bencardino, K, Palmeri, L, Bonazzina, EF, Tosi, F, Carlo Stella, G, Burrafato, G, Scaglione, F, Marsoni, S, Siravegna, G, Bardelli, A, Siena, S & Sartore-Bianchi, A 2018, 'Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies', Cancer Treatment Reviews, vol. 73, pp. 41-53. https://doi.org/10.1016/j.ctrv.2018.12.006
Mauri, Gianluca ; Pizzutilo, Elio Gregory ; Amatu, Alessio ; Bencardino, Katia ; Palmeri, Laura ; Bonazzina, Erica Francesca ; Tosi, Federica ; Carlo Stella, Giulia ; Burrafato, Giovanni ; Scaglione, Francesco ; Marsoni, Silvia ; Siravegna, Giulia ; Bardelli, Alberto ; Siena, Salvatore ; Sartore-Bianchi, Andrea. / Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer : Systematic review of different strategies. In: Cancer Treatment Reviews. 2018 ; Vol. 73. pp. 41-53.
@article{3f967e18f9f642c98b13305dace3a402,
title = "Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies",
abstract = "BACKGROUND: Despite advances in precision oncology and immunotherapy of tumors, little progress has been made in metastatic colorectal cancer (mCRC) in recent years. Therefore, making the most of available therapies is a necessity. Several studies, based on the pulsatile behavior of RAS clones under EGFR blockade, investigated whether readministration of EGFR-targeted agents is effective beyond second line.METHODS: A systematic review of studies of retreatment with anti-EGFR monoclonal antibodies has been performed from January 2005 to December 2018 according to PRISMA criteria from PubMed, ESMO and ASCO meetings libraries and Clinicaltrial.gov. Efficacy has been evaluated as objective response rate and survival in available publications. In addition, type and incidence of side effects occurring during on anti-EGFR retreatment have been considered.RESULTS: 26 publications have been retrieved, of which 20 full-text articles and 6 abstracts and categorized as for the retreatment strategy into five groups: rechallenge (n = 10), reintroduction (n = 4), sequence (n = 5), dose escalation (n = 1) and mixed (n = 6). Data of efficacy displayed high heterogeneity across different strategies (objective response rate, ORR = 0.0-53.8{\%}; disease control rate, DCR = 24.0-89.7{\%}), with best results in the setting of rechallenge (ORR = 2.9-53.8{\%}; DCR = 40.0-89.7{\%}).CONCLUSIONS: Rechallenge with anti-EGFR provides clinical benefit in molecularly selected mCRC patients beyond second line. Further ctDNA-guided studies comparing this option of treatment with current approved advanced line treatments are warranted.",
author = "Gianluca Mauri and Pizzutilo, {Elio Gregory} and Alessio Amatu and Katia Bencardino and Laura Palmeri and Bonazzina, {Erica Francesca} and Federica Tosi and {Carlo Stella}, Giulia and Giovanni Burrafato and Francesco Scaglione and Silvia Marsoni and Giulia Siravegna and Alberto Bardelli and Salvatore Siena and Andrea Sartore-Bianchi",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = "12",
day = "27",
doi = "10.1016/j.ctrv.2018.12.006",
language = "English",
volume = "73",
pages = "41--53",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer

T2 - Systematic review of different strategies

AU - Mauri, Gianluca

AU - Pizzutilo, Elio Gregory

AU - Amatu, Alessio

AU - Bencardino, Katia

AU - Palmeri, Laura

AU - Bonazzina, Erica Francesca

AU - Tosi, Federica

AU - Carlo Stella, Giulia

AU - Burrafato, Giovanni

AU - Scaglione, Francesco

AU - Marsoni, Silvia

AU - Siravegna, Giulia

AU - Bardelli, Alberto

AU - Siena, Salvatore

AU - Sartore-Bianchi, Andrea

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/12/27

Y1 - 2018/12/27

N2 - BACKGROUND: Despite advances in precision oncology and immunotherapy of tumors, little progress has been made in metastatic colorectal cancer (mCRC) in recent years. Therefore, making the most of available therapies is a necessity. Several studies, based on the pulsatile behavior of RAS clones under EGFR blockade, investigated whether readministration of EGFR-targeted agents is effective beyond second line.METHODS: A systematic review of studies of retreatment with anti-EGFR monoclonal antibodies has been performed from January 2005 to December 2018 according to PRISMA criteria from PubMed, ESMO and ASCO meetings libraries and Clinicaltrial.gov. Efficacy has been evaluated as objective response rate and survival in available publications. In addition, type and incidence of side effects occurring during on anti-EGFR retreatment have been considered.RESULTS: 26 publications have been retrieved, of which 20 full-text articles and 6 abstracts and categorized as for the retreatment strategy into five groups: rechallenge (n = 10), reintroduction (n = 4), sequence (n = 5), dose escalation (n = 1) and mixed (n = 6). Data of efficacy displayed high heterogeneity across different strategies (objective response rate, ORR = 0.0-53.8%; disease control rate, DCR = 24.0-89.7%), with best results in the setting of rechallenge (ORR = 2.9-53.8%; DCR = 40.0-89.7%).CONCLUSIONS: Rechallenge with anti-EGFR provides clinical benefit in molecularly selected mCRC patients beyond second line. Further ctDNA-guided studies comparing this option of treatment with current approved advanced line treatments are warranted.

AB - BACKGROUND: Despite advances in precision oncology and immunotherapy of tumors, little progress has been made in metastatic colorectal cancer (mCRC) in recent years. Therefore, making the most of available therapies is a necessity. Several studies, based on the pulsatile behavior of RAS clones under EGFR blockade, investigated whether readministration of EGFR-targeted agents is effective beyond second line.METHODS: A systematic review of studies of retreatment with anti-EGFR monoclonal antibodies has been performed from January 2005 to December 2018 according to PRISMA criteria from PubMed, ESMO and ASCO meetings libraries and Clinicaltrial.gov. Efficacy has been evaluated as objective response rate and survival in available publications. In addition, type and incidence of side effects occurring during on anti-EGFR retreatment have been considered.RESULTS: 26 publications have been retrieved, of which 20 full-text articles and 6 abstracts and categorized as for the retreatment strategy into five groups: rechallenge (n = 10), reintroduction (n = 4), sequence (n = 5), dose escalation (n = 1) and mixed (n = 6). Data of efficacy displayed high heterogeneity across different strategies (objective response rate, ORR = 0.0-53.8%; disease control rate, DCR = 24.0-89.7%), with best results in the setting of rechallenge (ORR = 2.9-53.8%; DCR = 40.0-89.7%).CONCLUSIONS: Rechallenge with anti-EGFR provides clinical benefit in molecularly selected mCRC patients beyond second line. Further ctDNA-guided studies comparing this option of treatment with current approved advanced line treatments are warranted.

U2 - 10.1016/j.ctrv.2018.12.006

DO - 10.1016/j.ctrv.2018.12.006

M3 - Review article

C2 - 30616224

VL - 73

SP - 41

EP - 53

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -